New Research Aims to Optimize Therapy Against Onchocerciasis

Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden o...

Full description

Saved in:
Bibliographic Details
Published in:Missouri medicine 2022-01, Vol.119 (1), p.55-59
Main Authors: Hong, Augustine R, Opoku, Nicholas O, Weil, Gary J, Kanza, Eric M, Gyasi, Michael E
Format: Article
Language:English
Subjects:
Clinical trials
Eye diseases
Ophthalmology
Parasites
Parasitic diseases
Patients
Tropical diseases
Worms
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 59
container_issue 1
container_start_page 55
container_title Missouri medicine
container_volume 119
creator Hong, Augustine R
Opoku, Nicholas O
Weil, Gary J
Kanza, Eric M
Gyasi, Michael E
description Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9312456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2707877295</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1166-8e618d11af76ac0782d3bae849fe061fd5a2bebb92e5508dbfd7f80b8d3a2d943</originalsourceid><addsrcrecordid>eNpdj81Kw0AYRWeh2Fp9h4AbN4H5yUwmIEIp_kExIHUdvmS-NFOSTJxJlPr0BuxGV3dxD4d7z8iSUq5ipThdkMsQDpSKTAt-QRZCUSFYIpfk7hW_ojcMCL5qorXtQjS6KB9G29lvjHYNehiO0XoPtg9jlPdV4yr0lYVgwxU5r6ENeH3KFXl_fNhtnuNt_vSyWW_jgTGlYo2KacMY1KmCiqaaG1EC6iSrkSpWGwm8xLLMOEpJtSlrk9aaltoI4CZLxIrc_3qHqezQVNiPHtpi8LYDfywc2OJv09um2LvPIhOMJ1LNgtuTwLuPCcNYdDZU2LbQo5tCwdN5VZryTM7ozT_04Cbfz_dmKlFSJoqn4gcdTmoN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2746554627</pqid></control><display><type>article</type><title>New Research Aims to Optimize Therapy Against Onchocerciasis</title><source>PubMed Central</source><creator>Hong, Augustine R ; Opoku, Nicholas O ; Weil, Gary J ; Kanza, Eric M ; Gyasi, Michael E</creator><creatorcontrib>Hong, Augustine R ; Opoku, Nicholas O ; Weil, Gary J ; Kanza, Eric M ; Gyasi, Michael E</creatorcontrib><description>Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.</description><identifier>ISSN: 0026-6620</identifier><identifier>PMID: 36033145</identifier><language>eng</language><publisher>Jefferson City: Missouri State Medical Association</publisher><subject>Clinical trials ; Eye diseases ; Ophthalmology ; Parasites ; Parasitic diseases ; Patients ; Tropical diseases ; Worms</subject><ispartof>Missouri medicine, 2022-01, Vol.119 (1), p.55-59</ispartof><rights>Copyright Missouri State Medical Association Jan/Feb 2022</rights><rights>Copyright 2022 by the Missouri State Medical Association 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312456/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312456/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids></links><search><creatorcontrib>Hong, Augustine R</creatorcontrib><creatorcontrib>Opoku, Nicholas O</creatorcontrib><creatorcontrib>Weil, Gary J</creatorcontrib><creatorcontrib>Kanza, Eric M</creatorcontrib><creatorcontrib>Gyasi, Michael E</creatorcontrib><title>New Research Aims to Optimize Therapy Against Onchocerciasis</title><title>Missouri medicine</title><description>Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.</description><subject>Clinical trials</subject><subject>Eye diseases</subject><subject>Ophthalmology</subject><subject>Parasites</subject><subject>Parasitic diseases</subject><subject>Patients</subject><subject>Tropical diseases</subject><subject>Worms</subject><issn>0026-6620</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdj81Kw0AYRWeh2Fp9h4AbN4H5yUwmIEIp_kExIHUdvmS-NFOSTJxJlPr0BuxGV3dxD4d7z8iSUq5ipThdkMsQDpSKTAt-QRZCUSFYIpfk7hW_ojcMCL5qorXtQjS6KB9G29lvjHYNehiO0XoPtg9jlPdV4yr0lYVgwxU5r6ENeH3KFXl_fNhtnuNt_vSyWW_jgTGlYo2KacMY1KmCiqaaG1EC6iSrkSpWGwm8xLLMOEpJtSlrk9aaltoI4CZLxIrc_3qHqezQVNiPHtpi8LYDfywc2OJv09um2LvPIhOMJ1LNgtuTwLuPCcNYdDZU2LbQo5tCwdN5VZryTM7ozT_04Cbfz_dmKlFSJoqn4gcdTmoN</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Hong, Augustine R</creator><creator>Opoku, Nicholas O</creator><creator>Weil, Gary J</creator><creator>Kanza, Eric M</creator><creator>Gyasi, Michael E</creator><general>Missouri State Medical Association</general><general>Journal of the Missouri State Medical Association</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>New Research Aims to Optimize Therapy Against Onchocerciasis</title><author>Hong, Augustine R ; Opoku, Nicholas O ; Weil, Gary J ; Kanza, Eric M ; Gyasi, Michael E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1166-8e618d11af76ac0782d3bae849fe061fd5a2bebb92e5508dbfd7f80b8d3a2d943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical trials</topic><topic>Eye diseases</topic><topic>Ophthalmology</topic><topic>Parasites</topic><topic>Parasitic diseases</topic><topic>Patients</topic><topic>Tropical diseases</topic><topic>Worms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hong, Augustine R</creatorcontrib><creatorcontrib>Opoku, Nicholas O</creatorcontrib><creatorcontrib>Weil, Gary J</creatorcontrib><creatorcontrib>Kanza, Eric M</creatorcontrib><creatorcontrib>Gyasi, Michael E</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Missouri medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hong, Augustine R</au><au>Opoku, Nicholas O</au><au>Weil, Gary J</au><au>Kanza, Eric M</au><au>Gyasi, Michael E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Research Aims to Optimize Therapy Against Onchocerciasis</atitle><jtitle>Missouri medicine</jtitle><date>2022-01-01</date><risdate>2022</risdate><volume>119</volume><issue>1</issue><spage>55</spage><epage>59</epage><pages>55-59</pages><issn>0026-6620</issn><abstract>Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.</abstract><cop>Jefferson City</cop><pub>Missouri State Medical Association</pub><pmid>36033145</pmid><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0026-6620
ispartof Missouri medicine, 2022-01, Vol.119 (1), p.55-59
issn 0026-6620
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9312456
source PubMed Central
subjects Clinical trials
Eye diseases
Ophthalmology
Parasites
Parasitic diseases
Patients
Tropical diseases
Worms
title New Research Aims to Optimize Therapy Against Onchocerciasis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A45%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Research%20Aims%20to%20Optimize%20Therapy%20Against%20Onchocerciasis&rft.jtitle=Missouri%20medicine&rft.au=Hong,%20Augustine%20R&rft.date=2022-01-01&rft.volume=119&rft.issue=1&rft.spage=55&rft.epage=59&rft.pages=55-59&rft.issn=0026-6620&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2707877295%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p1166-8e618d11af76ac0782d3bae849fe061fd5a2bebb92e5508dbfd7f80b8d3a2d943%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2746554627&rft_id=info:pmid/36033145&rfr_iscdi=true